Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke

Pharmacogenomics

Volumn 16, Issue 2, 2015, Pages 137-148

  Mitropoulou, Christina ^a   Fragoulakis, Vasilios ^b,c   Bozina, Nada ^d,e   Vozikis, Athanassios ^f   Supe, Svjetlana ^e   Bozina, Tamara ^d   Poljakovic, Zdravka ^e   Van Schaik, Ron H ^a   Patrinos, George P ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PATRAS   (Greece)

^c NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^d UNIVERSITY OF ZAGREB   (Croatia)

^e KBC Zagreb   (Croatia)

^f UNIVERSITY OF PIRAEUS   (Greece)

Author keywords

atrial fibrillation; cost effectiveness analysis; ischemic stroke; pharmacogenomics economic evaluation; warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROATIA; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; ECONOMIC EVALUATION; FEMALE; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; QUALITY ADJUSTED LIFE YEAR; ATRIAL FIBRILLATION; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; HEALTH CARE COST; PHARMACOGENETICS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICS AND NUMERICAL DATA; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; CROATIA; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUALITY-ADJUSTED LIFE YEARS; STROKE; WARFARIN;

EID: 84921688309     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.167     Document Type: Article

References (43)

1. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fbrillation: the Framingham Heart St udy. Circulation 110 (9), 1042-1046 (2004).
2. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fbrillation and futter in the United States. Am. J. Cardiol. 104(11), 1534-1539 (2009).
3. Rich MW. Epidemiology of atrial fbrillation. J. Interv. Card. Electrophysiol. 25(1), 3-8 (2009).
4. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fbrillation: incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, Age 75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratifcation scheme. Am. Heart J. 156(1), 57-64 (2008).
5. Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fbrillation: the Rotterdam study. Eur. Heart J. 27(8), 949-953 (2006).
6. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fbrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18), 2370-2375 (2001).
7. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ et al. Guidelines for the management of atrial fbrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31(19), 2369-2429 (2010).
8. DeWilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fbrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 92(8), 1064-1070 (2006).
9. Kirchhof P, Auricchio A, Bax J et al. Outcome parameters for trials in atrial fbrillation: executive summary. Eur. Heart J. 28(22), 2803-2817 (2007).
10. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fbrillation: 20-year follow-up of the Renfrew/Paisley study. Am. J. Med. 113(5), 359-364 (2002).
11. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fbrillation: a systematic review. Am. J. Med. 119(5), 448 e1-19 (2006).
12. Korantzopoulos P, Andrikopoulos G, Vemmos K, Goudevenos JA, Vardas PE. Atrial fbrillation and thromboembolic risk in Greece. Hellenic J. Cardiol. 53(1), 48-54 (2012).
13. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fbrillation. Epidemiology 14(6), 666-672 (2003).
14. Stewart S, MacIntyre K, MacLeod MM, Bailey AE, Capewell S, McMurray JJ. Trends in hospital activity, morbidity and case fatality related to atrial fbrillation in Scotland, 1986-1996. Eur. Heart J. 22(8), 693-701 (2001).
15. Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fbrillation in the UK. Heart 90(3), 286-292 (2004).
16. Ringborg A, Nieuwlaat R, Lindgren P et al. Costs of atrial fbrillation in fve European countries: results from the Euro Heart Survey on atrial fbrillation. Europace 10(4), 403-411 (2008).
17. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fbrillation in the United States. Value Health 9(5), 348-356 (2006).
18. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fbrillation: the FRACTAL registry. J. Cardiovasc. Electrophysiol. 18(6), 628-633 (2007).
19. McBride D, Mattenklotz AM, Willich SN, Brüggenjürgen B. The costs of care in atrial fbrillation and the effect of treatment modalities in Germany. Value Health 12(2), 293-301 (2009).
20. Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost of illness of atrial fbrillation: a systematic review of the recent literature. Europace 13(10), 1375-1385 (2011).
21. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fbrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 108(6), 711-716 (2003).
22. Bruggenjurgen B, Rossnagel K, Roll S et al. The impact of atrial fbrillation on the cost of stroke: the berlin acute stroke study. Value Health 10(2), 137-143 (2007).
23. Ghatnekar O, Glader EL. The effect of atrial fbrillation on stroke-related inpatient costs in Sweden: a 3-year analysis of registry incidence data from 2001. Value Health 11(5), 862-868 (2008).
24. Karampli E, Athanasakis K, Ollandezos M, Pavi E, Kyriopoulos J. Management of atrial fbrillation in the Greek healthcare setting. Hellenic J. Cardiol. 53(4), 273-278 (2012).
25. Landefeld, CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am. J. Med. 87(2), 144-152 (1989).
26. Fanikos J, Grasso-Correnti N, Shah R, Kucher N, Goldhaber SZ. Major bleeding complications in a specialized anticoagulation service. Am. J. Cardiol. 96(4), 595-598 (2005).
27. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientifc, and clinical issues. J. Thromb. Thrombolysis 25(1), 45-51 (2008).
28. Johnson JA, Gong L, Whirl-Carrillo M et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4), 625-629 (2011).
29. Weinstein MC, O'Brien B, Hornberger J et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-modeling studies. Value Health 6(1), 9-17 (2003).
30. Warfarin dosing. www.warfarindosing.org
31. Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl.), e152S-e184S (2012).
32. De Caterina RConnolly SJ Pogue J et al. Mortality predictors and effects of antithrombotic therapies in atrial fbrillation: insights from ACTIVE-W. Eur. Heart J. 31(17), 2133-2140 (2010).
33. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fbrillation. Circ. Cardiovasc. Qual. Outcomes 2(5), 429-436 (2009).
34. Leey JA, McCabe S, Koch JA, Miles TP. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fbrillation. Am. J. Geriatr. Pharmacother. 7(4), 197-203 (2009).
35. Desgagne A, Castilloux AM, Angers JF, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 13(5 Pt 1), 487-497 (1998).
36. Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 11(5), 886-897 (2008).
37. Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon. Outcomes Res. 3, 29-36 (2011).
38. You JH, Tsui KK, Wong RS, Cheng G. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fbrillation. PLoS ONE 7(6), e39640 (2012).
39. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fbrillation. Ann. Intern. Med. 150(2), 73-83 (2009).
40. You JH, Tsui KK, Wong RS, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin. Pharmacol. Ther. 86(5), 540-547 (2009).
41. You JH. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fbrillation: a cost-effectiveness analysis. Pharmacogenet. Genomics 24(1), 6-14 (2014).
42. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ. 10(2), 179-184 (2001).
43. Drummond MBarbieri M Cook J et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 12(4), 409-418 (2009).